IN8bio Inc. (INAB) Financial Statements (2025 and earlier)

Company Profile

Business Address EMPIRE STATE BUILDING
NEW YORK, NY 10118
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments21,28218,18237,021
Cash and cash equivalents21,28218,18237,021
Prepaid expense7901,258 
Other current assets270232 
Other undisclosed current assets2,2832,5621,959
Total current assets:24,62522,23438,980
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization1,3641,691704
Operating lease, right-of-use asset3,5134,1811,630
Property, plant and equipment3,5144,39797
Other noncurrent assets255255158
Other undisclosed noncurrent assets438281654
Total noncurrent assets:9,08410,8053,243
TOTAL ASSETS:33,70933,03942,223
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities3,8794,4331,630
Accounts payable9242,091395
Accrued liabilities2,9552,3421,235
Debt694682392
Other undisclosed current liabilities820707234
Total current liabilities:5,3935,8222,256
Noncurrent Liabilities
Long-term debt and lease obligation5258111,784
Finance lease, liability525811269
Liabilities, other than long-term debt2,8543,674 
Operating lease, liability2,8543,6741,515
Other undisclosed noncurrent liabilities   (1,515)
Total noncurrent liabilities:3,3794,4851,784
Total liabilities:8,77210,3074,040
Equity
Equity, attributable to parent24,93722,73238,183
Common stock432
Additional paid in capital116,15283,94170,872
Accumulated deficit(91,219)(61,212)(32,691)
Total equity:24,93722,73238,183
TOTAL LIABILITIES AND EQUITY:33,70933,03942,223

Income Statement (P&L) ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Revenues
(Other Income)
 330  
Gross profit: 330  
Operating expenses(30,337)(28,521)(14,653)
Other undisclosed operating loss(330)  
Operating loss:(30,337)(28,521)(14,653)
Nonoperating income
(Investment Income, Nonoperating)
   
Interest and debt expense(138)(53)(86)
Loss from continuing operations before income taxes:(30,475)(28,574)(14,739)
Income tax benefit 5,7414,5124,608
Other undisclosed income from continuing operations   
Loss from continuing operations:(24,734)(24,062)(10,131)
Loss before gain (loss) on sale of properties:(10,131)
Other undisclosed net loss(5,273)(4,459)(4,522)
Net loss:(30,007)(28,521)(14,653)
Other undisclosed net loss attributable to parent   
Net loss available to common stockholders, diluted:(30,007)(28,521)(14,653)

Comprehensive Income ($ in thousands)

9/30/2024
TTM
12/31/2023
12/31/2022
12/31/2021
Net loss:(30,007)(28,521)(14,653)
Comprehensive loss, net of tax, attributable to parent:(30,007)(28,521)(14,653)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: